[A double-blind comparative study of intracoronary administration of GE-0943 and urokinase: multicenter study]. 1989

H Kambara, and C Kawai, and N Kajiwara, and K Kammatsuse, and H Nitani, and S Sasayama, and K Kodama, and H Sato, and M Nobuyoshi, and M Nakashima

Coronary thrombolysis with plasminogen proactivator, GE-0943, was undertaken in patients with acute myocardial infarction and compared with urokinase. Fifty patients were given 6000 units of GE-0943 intracoronary and the totally occluded infarct-related arteries were recanalized in 92.0%. Fifty-four patients who were given 3000 units of GE-0943 intracoronary demonstrated a recanalization rate of 68.2%, while intracoronary administration of urokinase in 54 patients showed a recanalization rate of 70.4%. There was only one patient with hemorrhagic complication among GE-0943 3000-units group, none among GE-0943 6000-units group, and 5 among urokinase group. Thus, intracoronary administration of GE-0943 is very effective and safe with a dose up to 6000 units.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004792 Enzyme Precursors Physiologically inactive substances that can be converted to active enzymes. Enzyme Precursor,Proenzyme,Proenzymes,Zymogen,Zymogens,Precursor, Enzyme,Precursors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

H Kambara, and C Kawai, and N Kajiwara, and K Kammatsuse, and H Nitani, and S Sasayama, and K Kodama, and H Sato, and M Nobuyoshi, and M Nakashima
March 1986, Japanese heart journal,
H Kambara, and C Kawai, and N Kajiwara, and K Kammatsuse, and H Nitani, and S Sasayama, and K Kodama, and H Sato, and M Nobuyoshi, and M Nakashima
April 1985, The Journal of rheumatology,
H Kambara, and C Kawai, and N Kajiwara, and K Kammatsuse, and H Nitani, and S Sasayama, and K Kodama, and H Sato, and M Nobuyoshi, and M Nakashima
June 1992, Chest,
H Kambara, and C Kawai, and N Kajiwara, and K Kammatsuse, and H Nitani, and S Sasayama, and K Kodama, and H Sato, and M Nobuyoshi, and M Nakashima
January 1992, Journal of investigational allergology & clinical immunology,
H Kambara, and C Kawai, and N Kajiwara, and K Kammatsuse, and H Nitani, and S Sasayama, and K Kodama, and H Sato, and M Nobuyoshi, and M Nakashima
February 1988, The American journal of cardiology,
H Kambara, and C Kawai, and N Kajiwara, and K Kammatsuse, and H Nitani, and S Sasayama, and K Kodama, and H Sato, and M Nobuyoshi, and M Nakashima
October 1986, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
H Kambara, and C Kawai, and N Kajiwara, and K Kammatsuse, and H Nitani, and S Sasayama, and K Kodama, and H Sato, and M Nobuyoshi, and M Nakashima
October 1988, The Journal of rheumatology,
H Kambara, and C Kawai, and N Kajiwara, and K Kammatsuse, and H Nitani, and S Sasayama, and K Kodama, and H Sato, and M Nobuyoshi, and M Nakashima
January 1985, Contraception, fertilite, sexualite,
H Kambara, and C Kawai, and N Kajiwara, and K Kammatsuse, and H Nitani, and S Sasayama, and K Kodama, and H Sato, and M Nobuyoshi, and M Nakashima
January 1987, Therapie,
H Kambara, and C Kawai, and N Kajiwara, and K Kammatsuse, and H Nitani, and S Sasayama, and K Kodama, and H Sato, and M Nobuyoshi, and M Nakashima
January 1994, Clinical neuropharmacology,
Copied contents to your clipboard!